# Seqirus announces $140M expansion of Holly Springs flu vaccine facility

Seqirus, a CSL subsidiary, announced a $140 million expansion of its Holly Springs manufacturing facility in North Carolina to increase capacity for formulation, fill and finish of cell-based and adjuvanted influenza vaccines. The expansion will create 120 permanent jobs and is expected to be complete by 2020.

- Type: Expansion
- Announced: 2018-11-16
- Where: Holly Springs, North Carolina, United States
- Value: $140.0M
- Jobs: 120
- Starts operating: 2020
- Status: announced
- Products: cell-based influenza vaccines, adjuvanted influenza vaccines
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Seqirus](https://endata.com/companies/27952.md)
- [CSL](https://endata.com/companies/3244.md) (partner)

## Sources

- [newsroom.csl.com](https://newsroom.csl.com/2018-11-16-Seqirus-Announces-US-140-Million-Manufacturing-Expansion-to-Meet-Growing-Demand-for-Innovative-Cell-Based-Influenza-Vaccines), 2018-11-16: "We are deeply committed to developing innovative solutions, including cell-based vaccines, to help reduce deaths and severe illness caused by influenza."
- [prnewswire.com](https://www.prnewswire.com/news-releases/seqirus-announces-us-140-million-manufacturing-expansion-to-meet-growing-demand-for-innovative-cell-based-influenza-vaccines-300752090.html), 2018-11-16: "In just three years, we have quadrupled our supply of our cell-based influenza vaccine and this major investment will enable us to meet further demand."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.